Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $104 from $103 and keeps an Overweight rating on the shares. The firm updated the company’s estimates to reflect the cancellation of the JenaValve acquisition and management’s new 2026 outlook.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Stock (EW) Falls as FTC Wins Ruling to Block JenaValve Deal
- Edwards Lifesciences will not acquire JenaValve, updates FY26 guidance
- Edwards Lifesciences raises FY26 adjusted EPS view to $2.90-$3.05
- Edwards Lifesciences upgraded to Buy from Hold at TD Cowen
- Edwards Lifesciences price target raised to $108 from $104 at Goldman Sachs